h2 Section Title heading
After graduation, Portero will become vice president of Partnerships and Innovation at Orphan Therapeutics Accelerator, a nonprofit biotech company focused on developing clinical therapies for ultra-rare diseases. In the U.S., so-called orphan diseases are those conditions that affect fewer than 200,000 people. According to Portero, the Orphan Therapeutics Accelerator focuses on the thousands of rare genetic diseases for which a therapy could be sustainably marketed but has failed to attract sufficient interest from traditional investors.
“About a month into my time at Hopkins, I connected with experienced collaborators in my field who wanted to work together to launch the Orphan Therapeutics Accelerator,” Portero explains. “I’m proud to have identified a gap in helping people with orphan diseases and I’m proud of the perseverance it has required to bring this challenging and ambitious mission into reality.”
Jamshidi and Portero will receive their degrees at the Carey Business School commencement ceremony on May 20. Jamshidi will be giving an address on behalf of the Class of 2025.
”Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolorev."
Paragraph 1
H3 Section Title
After graduation, Portero will become vice president of Partnerships and Innovation at Orphan Therapeutics Accelerator, a nonprofit biotech company focused on developing clinical therapies for ultra-rare diseases. In the U.S., so-called orphan diseases are those conditions that affect fewer than 200,000 people. According to Portero, the Orphan Therapeutics Accelerator focuses on the thousands of rare genetic diseases for which a therapy could be sustainably marketed but has failed to attract sufficient interest from traditional investors.
“About a month into my time at Hopkins, I connected with experienced collaborators in my field who wanted to work together to launch the Orphan Therapeutics Accelerator,” Portero explains. “I’m proud to have identified a gap in helping people with orphan diseases and I’m proud of the perseverance it has required to bring this challenging and ambitious mission into reality.”
Jamshidi and Portero will receive their degrees at the Carey Business School commencement ceremony on May 20. Jamshidi will be giving an address on behalf of the Class of 2025.
H4 Section Title
After graduation, Portero will become vice president of Partnerships and Innovation at Orphan Therapeutics Accelerator, a nonprofit biotech company focused on developing clinical therapies for ultra-rare diseases. In the U.S., so-called orphan diseases are those conditions that affect fewer than 200,000 people.
- Bullet 1
- Erat tristique: accumsan lorem mattis pulvinar suscipit. Porttitor lorem lacinia laoreet; placerat arcu mus cubilia vitae. Accumsan nibh nec ornare mi semper habitasse scelerisque.
- Bullet 2
- Consectetur adipiscing elit sed do.
- Consectetur adipiscing elit sed do.
- Accumsan nibh nec ornare mi semper habitasse scelerisque.
- Porttitor lorem lacinia laoreet; placerat arcu mus cubilia vitae.
- Consectetur adipiscing elit sed do.
- Consectetur adipiscing elit sed do.
- Consectetur adipiscing elit sed do.
- Porttitor lorem lacinia laoreet; placerat arcu mus cubilia vitae.
- Bullet 2
- Erat tristique: accumsan lorem mattis pulvinar suscipit. Porttitor lorem lacinia laoreet; placerat arcu mus cubilia vitae.
- Accumsan nibh nec ornare mi semper habitasse scelerisque.
H5 Section Title
After graduation, Portero will become vice president of Partnerships and Innovation at Orphan Therapeutics Accelerator, a nonprofit biotech company focused on developing clinical therapies for ultra-rare diseases. In the U.S., so-called orphan diseases are those conditions that affect fewer than 200,000 people.
H6 Section Title
- Accumsan nibh nec ornare mi semper habitasse scelerisque.
- Porttitor lorem lacinia laoreet; placerat arcu mus cubilia vitae.
- Consectetur adipiscing elit sed do.
- Consectetur adipiscing elit sed do.
- Consectetur adipiscing elit sed do.
- Porttitor lorem lacinia laoreet; placerat arcu mus cubilia vitae.
- Porttitor lorem lacinia laoreet; placerat arcu mus cubilia vitae.
join the newsletter
Paragraph 1
h3 Title Two Column
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est.
